Literature DB >> 18667845

Progastrin-releasing peptide: stability in plasma/serum and upper reference limit.

Marianne S Nordlund1, Johan Bjerner, David J Warren, Kjell Nustad, Elisabeth Paus.   

Abstract

BACKGROUND: Progastrin-releasing peptide (proGRP) is a promising tumor marker for small cell lung cancer (SCLC). Here we study the stability of proGRP in serum and plasma, as well as proGRP levels in healthy individuals, to provide a framework for clinical studies.
METHODS: Serum, with and without protease inhibitors, and plasma from SCLC patients and healthy individuals were assayed for proGRP immediately after collection and following various storage conditions.
RESULTS: No degradation was observed in serum or plasma after storage for 4 weeks at -30 degrees C. Serum proGRP levels were stable for up to 3 days at 4 degrees C, but decreased at room temperature. Addition of protease inhibitors to patient serum did not markedly improve stability. In EDTA plasma, proGRP concentrations increased upon storage in some samples at room temperature and 4 degrees C. When assayed immediately after collection, no significant variations in proGRP concentrations were observed between serum and EDTA plasma (n = 171). A 97.5-percentile reference limit of 58.9 ng/l was calculated from data from 806 individuals. However, proGRP levels were significantly correlated with age, sex, creatinine concentrations, body mass index and smoking.
CONCLUSION: Serum is the preferred material for measuring proGRP, provided it is stored at 4 degrees C and assayed within 3 days. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667845     DOI: 10.1159/000148188

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

Review 1.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

2.  Characteristics and clinical validity of two immunoassays for ProGRP.

Authors:  Marianne S Nordlund; Petra Stieber; Odd Terje Brustugun; David J Warren; Elisabeth Paus
Journal:  Tumour Biol       Date:  2012-03-08

3.  Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.

Authors:  Hye-Ran Kim; In-Jae Oh; Myung-Geun Shin; Joon-Seok Park; Hyun-Jung Choi; Hee-Jung Ban; Kyu-Sik Kim; Young-Chul Kim; Jong-Hee Shin; Dong-Wook Ryang; Soon-Pal Suh
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

4.  Instability of Plasma and Serum Progastrin-Releasing Peptide During Repeated Freezing and Thawing.

Authors:  Jae-Eun Lee; Jin-Hyun Lee; Maria Hong; Seul-Ki Park; Ji-In Yu; So-Youn Shin; Shine Young Kim
Journal:  Osong Public Health Res Perspect       Date:  2016-11-16

Review 5.  Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.

Authors:  Ewa Wojcik; Jan Kanty Kulpa
Journal:  Lung Cancer (Auckl)       Date:  2017-11-28

6.  Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.

Authors:  Xiao-Yuan Wu; Yang-Bo Hu; Hui-Juan Li; Bing Wan; Chen-Xi Zhang; Bin Zhang; Huan Hu; Qun Zhang; Tang-Feng Lv; Ping Zhan; Yong Song
Journal:  J Cell Mol Med       Date:  2018-07-10       Impact factor: 5.310

7.  The influence of different blood samples treatment methods on pro-gastrin-releasing peptide.

Authors:  Huiqin Jiang; Ling Luo; Kang Xiong; Chengwen He; Huaizhou Wang; Yanghua Qin
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

8.  New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.

Authors:  Benjamin Nisman; Hovav Nechushtan; Haim Biran; Nir Peled; Hadas Gantz-Sorotsky; Victoria Doviner; Marina Perelman; Jair Bar; Amir Onn; Beatrice Uziely; Tamar Peretz
Journal:  Br J Cancer       Date:  2016-01-26       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.